| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-04-30 | Cx611 | rheumatoid arthritis |
2 | Tigenix (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-04-30 | lifitegrast | dry eye disease |
3 | Shire (UK-USA) | Ophtalmological diseases |
| 2014-04-30 | NuQ® diagnostic platform | breast cancer |
prospective study | VolitionRX (Singapore) - Rheinische Friedrich-Wilhelms-Universität Bonn (Bonn University - Germany) | Cancer - Oncology |
| 2014-04-29 | Jetrea® (ocriplasmin) | 4 | Thrombogenics (Belgium) | Ophtalmological diseases | |
| 2014-04-29 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | glioblastoma, glioma | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-04-28 | olesoxime | spinal muscular atrophy (SMA) |
2-3 | Trophos (France) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2014-04-28 | MGN1703 (lefitolimod) | 1 | Mologen (Germany) | Cancer - Oncology | |
| 2014-04-28 | CV301 | bladder cancer |
2 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2014-04-28 | Envarsus® (LCP-Tacro™) | prevention of graft rejection in kidney transplantation |
2 | Veloxis Pharmaceuticals (Denmark) | Transplantation |
| 2014-04-24 | V81444 (adenosine A2A receptor antagonist) | Parkinson’s disease |
1b-2 | Vernalis (UK) | Neurodegenerative diseases - CNS diseases |
| 2014-04-24 | Nexavar® (sorafenib) | locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer |
3 | Bayer HealthCare (Germany) Onyx Pharmaceuticals (USA) | Cancer - Oncology |
| 2014-04-24 | oral insulin ORMD-0801 | type 2 diabetes |
2a | Oramed Pharmaceuticals (Israel) | Metabolic diseases |
| 2014-04-24 | Kuvan® (sapropterin dihydrochloride) | phenylketonuria |
3b | Merck Serono, a Merck KGaA company (Germany) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2014-04-24 | Soliris® (eculizumab) | relapsing neuromyelitis optica (NMO) | 3 | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Neurological diseases |
| 2014-04-24 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | ovarian carcinoma, endometrial carcinoma, cervical carcinoma, breast cancer | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-04-22 | somatoprim (DG3173 - somatostatin analogue) | acromegaly |
1b | Aspireo Pharmaceuticals (Israel) | Rare diseases - Hormonal diseases - Endocrine diseases |
| 2014-04-21 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML | 1 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-04-16 | Viaskin® Peanut | peanut allergy |
pediatric study | DBV Technologies (France) AP-HP (France) | Allergic diseases - Immunological diseases |
| 2014-04-15 | nano-enabled intranasal teriparatide | osteoporosis |
1 | Critical Pharmaceuticals (UK) Nottingham University Hospitals NHS Trust (UK) | Bone diseases |
| 2014-04-15 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) and Dacogen®(decitabine) | acute myeloid leukemia (AML) | 1 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
